PODD:NSD-Insulet Corporation (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 300.49

Change

0.00 (0.00)%

Market Cap

USD 20.70B

Volume

0.24M

Avg Analyst Target

USD 298.13 (-0.79%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-16 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology Inc

N/A

USD46.66B 67.21 49.74
ABMD Abiomed Inc

N/A

USD15.95B 103.89 50.66
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

N/A

USD11.66B 49.76 25.84
TNDM Tandem Diabetes Care Inc

N/A

USD7.90B 1,216.99 251.84
SWAV ShockWave Medical Inc

N/A

USD6.92B N/A N/A
INMD InMode Ltd

N/A

USD6.51B 56.98 39.02
IART Integra LifeSciences Holdings ..

N/A

USD5.72B 28.04 18.47
LIVN LivaNova PLC

N/A

USD4.46B 77.40 N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67

ETFs Containing PODD

Symbol Name Weight Mer Price(Change) Market Cap
SCHM Schwab U.S. Mid-Cap ETF 0.00 % 0.04 %

N/A

USD9.68B
SLIM The Obesity ETF 0.00 % 0.35 %

N/A

USD0.01B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

N/A

USD0.15B
HTEC Robo Global Healthcare Te.. 0.00 % 0.68 %

N/A

USD0.24B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.55% 56% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.55% 56% F 63% D
Trailing 12 Months  
Capital Gain 21.00% 44% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.00% 44% F 47% F
Trailing 5 Years  
Capital Gain 663.93% 96% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 663.93% 96% A 94% A
Average Annual (5 Year Horizon)  
Capital Gain 60.56% 76% C 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.56% 76% C 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 36.28% 80% B- 51% F
Risk Adjusted Return 166.90% 100% A+ 99% A+
Market Capitalization 20.70B 99% A+ 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2,208.27 4% F 1% F
Price/Book Ratio 43.99 3% F 2% F
Price / Cash Flow Ratio 246.38 4% F 2% F
EV/EBITDA 247.98 11% F 4% F
Management Effectiveness  
Return on Equity -5.97% 70% C- 47% F
Return on Invested Capital 3.70% 81% B- 62% D-
Return on Assets 2.08% 85% B 65% D
Debt to Equity Ratio 172.91% 17% F 12% F
Technical Ratios  
Short Ratio 8.04 20% F 14% F
Short Percent 3.43% 58% F 45% F
Beta 0.68 77% C+ 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.